Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters

被引：0
|
作者：
Patrycja Koszałka
Ewa Szmit
Andrzej Myśliwski
Jacek Bigda
机构：
[1] Medical University of Gdańsk,Department of Medical Biotechnology, Division of Cell Biology, Intercollegiate Faculty of Biotechnology
[2] Medical University of Gdańsk,Department of Histology and Immunology
来源：
Archivum Immunologiae et Therapiae Experimentalis | 2007年 / 55卷
关键词：
TNF; melanoma; tumor vasculature; immune modulation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 279
页数：12
相关论文
共 50 条
  • [31] Compromised anti-tumor responses in tumor necrosis factor-α knockout mice
    Baxevanis, CN
    Voutsas, IF
    Tsitsilonis, OE
    Tsiatas, ML
    Gritzapis, AD
    Papamichail, M
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2000, 30 (07) : 1957 - 1966
  • [32] MODULATION OF THE ANTI-TUMOR ACTIVITY OF TUMOR NECROSIS FACTOR BY MONOCLONAL-ANTIBODIES
    RATHJEN, D
    ASTON, R
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1989, 93 (04) : 571 - 571
  • [33] Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis
    Egberts, Jan-Hendrik
    Cloosters, Vera
    Noack, Andreas
    Schniewind, Bodo
    Thon, Lutz
    Klose, Stefanie
    Kettler, Bastian
    von Forstner, Corinna
    Kneitz, Christian
    Tepel, Juergen
    Adam, Dieter
    Wajant, Harald
    Kalthoff, Holger
    Trauzold, Anna
    CANCER RESEARCH, 2008, 68 (05) : 1443 - 1450
  • [34] Effect of tumor excision on NK cytotoxic activity and formation of metastases of Bomirski melanoma in hamsters
    Mysliwski, A
    Sosnowska, D
    Bigda, J
    NEOPLASMA, 1996, 43 (05) : 311 - 313
  • [35] Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor α-expressing cells
    Mitoma, Hiroki
    Horiuchi, Takahiko
    Tsukamoto, Hiroshi
    Tarnimoto, Yasuhiro
    Kimoto, Yasutaka
    Uchino, Ayumi
    To, Kentaro
    Harashima, Shin-ichi
    Hatta, Nobuaki
    Harada, Mine
    ARTHRITIS AND RHEUMATISM, 2008, 58 (05): : 1248 - 1257
  • [36] Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor
    Vande Casteele, Niels
    Abreu, Maria T.
    Flier, Sarah
    Papamichael, Konstantinos
    Rieder, Florian
    Silverberg, Mark S.
    Khanna, Reena
    Okada, Lauren
    Yang, Lei
    Jain, Anjali
    Cheifetz, Adam S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (02) : 465 - +
  • [37] Treatment Persistence Among Anti-Tumor Necrosis Factor-experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti-Tumor Necrosis Factor Agent
    Zhdanava, Maryia
    Burbage, Sabree
    Boonmak, Porpong
    Kachroo, Sumesh
    Shah, Aditi
    Godwin, Bridget
    Pilon, Dominic
    CLINICAL THERAPEUTICS, 2025, 47 (03) : 204 - 211
  • [38] Exploring conditions for redistribution of anti-tumor necrosis factors to reduce spillage: A study on the quality of anti-tumor necrosis factor home storage
    de Jong, Marin J.
    Pierik, Marieke J.
    Peters, Andy
    Roemers, Mark
    Hilhorst, Veronique
    van Tubergen, Astrid
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (02) : 426 - 430
  • [39] A comparative study into the mechanisms of action of anti-tumor necrosis factor α, anti-CD4, and combined anti-tumor necrosis factor α/anti-CD4 treatment in early collagen-induced arthritis
    Marinova-Mutafchieva, L
    Williams, RO
    Mauri, C
    Mason, LJ
    Walmsley, MJ
    Taylor, PC
    Feldmann, M
    ARTHRITIS AND RHEUMATISM, 2000, 43 (03): : 638 - 644
  • [40] Cloning, expression, purification of rat tumor necrosis factor and demonstration of its antitumor activity in Bomirski amelanotic melanoma
    Koszalka, P
    Breza, H
    Bigda, J
    NEOPLASMA, 1998, 45 (03) : 162 - 168
12345